Pasithea Therapeutics (KTTA) Return on Sales (2022)
Pasithea Therapeutics (KTTA) posted Return on Sales of 0.14% for Q4 2022, down 885.45% sequentially from 0.02% in Q3 2022.
Pasithea Therapeutics (KTTA) Return on Sales (2022) Analysis & Trends
Pasithea Therapeutics has reported Return on Sales for 1 years, with the latest figure at 0.14% in Q4 2022.
- Quarterly Return on Sales changed N/A year-over-year to 0.14% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.08% (changed N/A YoY) and the FY2022 annual result came in at 0.05%, up 140.0% from the prior year.
- Return on Sales eased to 0.14% in Q4 2022 per KTTA's latest filing, from 0.02% in the prior quarter.
- Over five years, Return on Sales peaked at 0.02% in Q3 2022 and troughed at 0.34% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -0.14% |
| Sep 30, 2022 | 0.02% |
| Jun 30, 2022 | -0.34% |
| Mar 31, 2022 | -0.24% |